Answers are grounded in this paper and cite their sources.
The advent of tyrosine kinase inhibitors (TKI) has profoundly changed the current therapeutic approach in some hematologic malignancies, including BCR-ABL1 -positive acute lymphoblastic leukemia (ALL). Recently, next-generation genomic methods have uncovered various alterations in ALL that lead to
No takes yet. Share an insight, caveat, or question.
Lengliné et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: